Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.14 +2.47%

+$0.76 today

Market cap
$365.67M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.25M

Average 0.16M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$77.17M

FY 2025 · Annual

Investing Cash Flow

$14.00M

FY 2025 · Annual

Financing Cash Flow

$30.43M

FY 2025 · Annual

-83.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.52M)(55.19M)(36.32M)(75.14M)(90.35M)
Depreciation & Amortization947K3.2M3.3M3.25M3.09M
Deferred Income Tax00(105K)00
Stock-Based Compensation896K1.25M1.42M8.32M14.18M
Change in Working Capital1.6M(2.7M)(4.02M)(5.96M)268K
Accounts Receivables00000
Inventory00000
Accounts Payables2.98M(3.61M)667K(77K)627K
Other Working Capital(1.39M)912K(4.69M)(5.88M)(359K)
Other Non-Cash Items679K608K(15.69M)(1.07M)(4.37M)
Operating Cash Flow(46.4M)(52.82M)(51.42M)(70.6M)(77.17M)
Capital Expenditures(18.37M)(2.23M)(321K)(808K)(1.18M)
Acquisitions (Net)00000
Purchases of Investments000(198.45M)(269.51M)
Sales of Investments005M74M284.7M
Other Investing Activities0020.96M00
Investing Cash Flow(18.37M)(2.23M)25.64M(125.26M)14M
Debt Repayment0(1K)(29K)(52K)(61K)
Common Stock Issued287K73K92.34M189.59M30.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00168K(5.47M)0
Financing Cash Flow51.06M66.53M92.48M184.07M30.43M
Effect of Forex Changes00000
Net Change in Cash(13.71M)11.48M66.7M(11.79M)(32.74M)
Free Cash Flow(64.77M)(55.05M)(51.74M)(71.41M)(78.36M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$90.4M
+ D&A$3.1M
+ Stock-Based Comp$14.2M
+ Deferred Tax$0
+ Working Capital$268.0K
- Other Non-Cash-$4.4M
= Operating Cash Flow-$77.2M
- Capex-$1.2M
= Free Cash Flow-$78.4M

Analysis

FY2025 free cash flow is -$78.4M. FCF conversion is 86.7% of net income. Operating cash flow was -$77.2M, with capex of -$1.2M. The largest bridge item is Stock-Based Comp at $14.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13GSC 13G filingOct 7, 2026
SC 13GSC 13G filingOct 6, 2026
4Statement of changes in beneficial ownershipOct 2, 2026

Does NGNE generate free cash flow?

Neurogene Inc. (NGNE) generated -$78.36M of free cash flow in fiscal 2025.

How much operating cash flow does NGNE produce?

Operating cash flow was -$77.17M, before capital expenditures of $1.18M.